ALK and neoplasm: In this context, RMS tumours that overexpress ALK may constitute a subset at high likelihood for drug response, whereas those harbouring mutations in the kinase domain or expressing wild-type ALK receptor at physiological levels may not be sensitive to targeted treatments.